Integrating molecular diagnostics to predict progression from monoclonal gammopathy of undetermined significance (MGUS) to myeloma and intercept & treat individuals at highest risk
- Collaborators: Udo Oppermann, Karthik Ramasamy, Anna Schuh, Chris Schofield
- Challenge: Predicting progression
Oxford researchers are analysing and linking comprehensive primary to secondary care electronic health records (EHRs) and molecular stratification outputs from prospective studies such as the OxPLoreD programme. This will allow clinicians to better predict which individuals with MGUS will progress to myeloma and intercept and treat those most likely to progress, for example in the DEFENCE trial.